Position of the Transparency Council – Talzenna (talazoparib)
At its meeting on 16 December 2024, the Transparency Council adopted position No. 150/2024 on the evaluation of the drug Talzenna (talazoparib) under drug program B.56 “Treatment of patients with prostate cancer (ICD10: C61)”